PPACA Impact and Opportunities for the Life Sciences Industry Explored

Kevin Sweeney is Chair of Polsinelli Shughart’s multidisciplinary Life Sciences practice group and a senior member of its Corporate Finance group. He has more than 30 years experience in handling mergers and acquisitions, public and private securities offerings, venture capital financing, technology transfer, and other complex financial and strategic transactions for clients in a wide variety of industries, with a special emphasis in serving as a strategic advisor to the top management of life science companies of all types and stages of development. He is a strategic partner to many emerging and growth companies, assisting in the development and implementation of their business, financial and legal goals.

Mr. Sweeney uses his broad contacts in the national scientific, academic, business and financial communities to assist numerous emerging, growth, and established entities that advance human health, animal health, plant science, “green” and industrial technologies, and biosafety and homeland security sciences, as well as computer and software technologies.

Steven K. Stranne is a physician and lawyer with over 18 years of experience in Washington, D.C. designing, implementing and overseeing complex legislative and regulatory initiatives involving Congress, the Centers for Medicare & Medicaid Services (CMS), numerous other federal agencies within the U.S. Department of Health and Human Services (HHS) and the Medicare Administrative Contractors. He currently serves as policy counsel to several large non-profit health care associations, and he represents numerous health care providers and manufacturers of pharmaceuticals, biologics and medical devices.

Dr. Stranne helps clients to develop and implement strategies to secure appropriate reimbursement, coding and coverage policies for new and existing medical technologies and clinical services. He also works with the boards and leadership of manufacturers, health care providers and associations to assist with strategic planning in the context of the evolving regulatory and reimbursement landscape for health care services, drugs and devices. He provides unique experience in shaping public policy and works to develop novel strategies for clients to achieve their objectives by combining his ability to understand the health care sector and to interpret and help shape the relevant clinical literature, legislation and federal regulations.

R.T. (Terry) Hisey is the Vice Chairman and U.S. Life Sciences Leader for Deloitte LLP. In this role, Terry leads the firm’s service efforts in the areas of audit, tax, strategy, performance improvement and technology consulting to assist clients in achieving sustainable competitive advantage through strategic change. His Life Sciences experience spans the entire value chain including drug discovery & development, commercial operations, production & distribution, and regulatory compliance. As Chairman of the Life Sciences Advisory Board for Deloitte Research and Steering Committee member for the Deloitte Center for Health Solutions, Terry guides thought leadership and advises clients on transformative opportunities in the industry including comparative effectiveness, informatics, social media and globalization. In addition to his client work, Terry is a noted industry authority, frequent speaker, a Strategy Advisor to Pharmaceutical Executive Magazine, and guest lecturer at several schools including the University of Pennsylvania, and the University of California at Berkeley. Terry is also a member of several industry associations and advisory boards.

Jerry is a Partner in Oliver Wyman’s Health and Life Sciences Practice. He is a trusted advisor to senior executives across pharma and biotech, advising them on their most important decisions — to enter new markets, to undertake acquisitions or to realign business models. His recent work has focused on helping pharma prepare for the value-based healthcare, driven in part by the Affordable Care Act and other reform efforts, crafting strategies to profit and win in the transition from ‘fee for service’ medicine and ‘unit volume’ to the world where value – low cost, high quality – commands price.

Before joining Oliver Wyman, Jerry was a Vice President at IMS Health, leading its Product & Portfolio Strategy practice. Earlier, Jerry led the Life Sciences practice at Strategic Decisions Group. Jerry holds a B.A. in International Relations and an M.B.A. from Stanford University.